1. Home
  2. TIC vs DNLI Comparison

TIC vs DNLI Comparison

Compare TIC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TIC

Acuren Corporation

HOLD

Current Price

$11.45

Market Cap

2.3B

Sector

N/A

ML Signal

HOLD

Logo Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc.

HOLD

Current Price

$17.97

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIC
DNLI
Founded
1991
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.6B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TIC
DNLI
Price
$11.45
$17.97
Analyst Decision
Buy
Strong Buy
Analyst Count
4
13
Target Price
$14.63
$31.58
AVG Volume (30 Days)
2.2M
1.4M
Earning Date
02-03-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,284,070,000.00
N/A
Revenue This Year
$41.97
N/A
Revenue Next Year
$42.94
$3,973.10
P/E Ratio
N/A
N/A
Revenue Growth
16.15
N/A
52 Week Low
$8.76
$10.57
52 Week High
$14.94
$24.35

Technical Indicators

Market Signals
Indicator
TIC
DNLI
Relative Strength Index (RSI) 59.74 54.81
Support Level $11.04 $17.88
Resistance Level $11.70 $17.95
Average True Range (ATR) 0.53 0.85
MACD 0.13 0.20
Stochastic Oscillator 81.06 68.85

Price Performance

Historical Comparison
TIC
DNLI

About TIC Acuren Corporation

TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Share on Social Networks: